At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.
Analyze the difference in intravenous sedation requirements in patients with COVID-19. Patients who were assisted by a mechanical ventilator with sevoflurane versus conventional sedation.
Study Type
OBSERVATIONAL
Enrollment
43
Sevoflurane administered with AnaConDa device
Hospital H+ Queretaro
Querétaro City, Querétaro, Mexico
Intravenous sedation requirements
Amount of intravenous sedation required
Time frame: 7 days
Delirium
Number of patients that suffered delirium
Time frame: Hospital stay (up to 30 days)
Acute kidney injury
Number of patients that suffered delirium
Time frame: Hospital stay (up to 30 days)
VAP
Number of patients that suffered ventilation acquired pneumonia
Time frame: Hospital stay (up to 30 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.